Introduction
Hematopoietic progenitor cells are highly susceptible to the cytotoxicity of anticancer drugs, and leukocytopenia causing an increased risk of septic infections is a common complication of cancer treatment. Myeloid and erythroid progenitor cells express very low levels of the multidrug resistance gene, MDR1, while pluripotent hematopoietic stem cells and some lymphocytes are relatively protected by higher expression levels. [1] [2] [3] [4] The product of this gene is P-glycoprotein (P-gp), a plasma membrane-associated drug efflux pump which extrudes a broad variety of natural toxins and their derivatives outwardly across the plasma membrane. Cells expressing P-gp are insensitive to the cytotoxicity of anticancer drugs because the intracellular drug concentrations may be reduced below a non-toxic threshold (reviewed in Ref. 5 ). Substrates of this multidrug transporter include many drugs used in clinical cancer treatment, eg Vinca alkaloids, taxanes, anthracyclines, epipodophyllotoxins, colchicine and actinomycin D. Hence, overexpression of P-gp is associated with failure of anticancer chemotherapy in various malignancies.
tion increased the frequency of chemoresistant colonies up to 40% over the number of unselected cells. Colchicine and daunomycin were equally efficient in increasing drug resistance ex vivo, but colchicine-preselected cells rescued lethally irradiated mice under conditions where daunomycinselected bone marrow cells failed to do so. Hence, while hematopoietic cells can be protected by MDR1, the selection strategy is critical for repopulation of bone marrow with transduced cells. Preselection in culture before transplantation significantly increased P-gp expression and chemoresistance in vivo in mice reconstituted with transduced bone marrow cells. This study may help to facilitate the use of MDR1 as a selectable marker in gene therapy of the hematopoietic system. Gene Therapy (2000) 7, 348-358.
The use of MDR1 or other chemoresistance genes for protection of normal hematopoietic cells by gene therapy has been proposed. [9] [10] [11] Recently, clinical trials were conducted to investigate the feasibility and safety of retroviral transfer of MDR1 to hematopoietic progenitor cells of cancer patients and reinfusion of transduced cells. [12] [13] [14] [15] The long-term goal of this approach is to achieve safe dose-intensification of drug treatment which may improve the rate of lasting remissions. Transduction efficiency, however, has been low using existing protocols, but one recent study suggests that MDR1-transduced hematopoietic cells may have a growth advantage in patients subsequently exposed to chemotherapy. 15 These clinical studies are based on preclinical models in which the ability of MDR1 to protect the bone marrow of transgenic mice against drug toxicity has been demonstrated. 16, 17 In addition, the feasibility of retroviral transfer of a human MDR1 cDNA to murine hematopoietic progenitor/stem cells with the capacity of engrafting recipient mice has been shown. [18] [19] [20] [21] [22] Transduction of human CD34
+ cells with retroviruses containing the MDR1 sequence has also been accomplished at lower frequencies. [23] [24] [25] Besides protection of drug-sensitive cells from the sideeffects of chemotherapy, drug resistance genes are of additional interest for clinical applications because they may serve as selectable markers in vivo. The products of chemoresistance genes like MDR1 can be used in live organisms, unlike proteins that confer resistance to drugs like hygromycin, neomycin or puromycin because of the toxicity profile or pharmacokinetics of their respective substrates. 26 An attractive application is to coexpress drug-selectable genes with genes that correct genetically determined disorders from polycistronic cassettes or from open reading frames encoding fusion proteins. Exposure to cytotoxic drugs should enhance expression of both the chemoresistance gene and the second gene in target cells. Thereby, low expression of otherwise nonselectable genes should be restored. To this end, vectors have been developed in which MDR1 is combined with genes that correct disorders of the hematopoietic system such as Gaucher's disease, Fabry's disease, severe combined immunodeficiency (SCID) and chronic granulomatous disease. [27] [28] [29] [30] A bicistronic vector that contained MDR1 and glucocerebrosidase, the enzyme which causes Gaucher's disease if mutated, facilitated complete restoration of the enzyme activity in patients' fibroblasts while non-selected cells expressed only minute amounts of glucocerebrosidase. 31 Whereas selection of transduced fibroblasts or cancer cells can easily be accomplished with many substrates of P-gp, the ideal selection strategy for hematopoietic cells has not yet been established. The low frequencies of transduced hematopoietic progenitor cells in the first clinical trials were not sufficient to confer adequate resistance to anticancer chemotherapy. Thus, transduction procedure and selection strategies for hematopoietic cells will require further optimization. A major obstacle to efficient drug selection may be that certain cytotoxic substrates of P-gp are mainly active against more mature, non-clonogenic precursor cells. 32 Compounds that eliminate exclusively non-clonogenic hematopoietic cells would not be useful for selection because they cannot provide a selective advantage to transduced resistant cells in the regrowing population. On the other hand, selection with high concentrations of anticancer drugs may bear the risk that drug-treated hematopoietic cells lose their clonogenicity in vivo and ability to expand in bone marrow, resulting in engraftment failure.
We have recently reported that treatment with daunomycin and colchicine increases expression of MDR1 mRNA and protein levels in hematopoietic cells due to clonal expansion of transduced cells. 33 In this work, we have investigated conditions under which MDR1-transduced hematopoietic cells are capable of engrafting in recipient bone marrow and rescuing lethally irradiated mice. Since the efficiency of gene transfer to hematopoietic cells has been unsatisfactory in clinical trials, this situation was mimicked by studying inefficient transduction with a low-titer vector in comparison to more efficient gene transfer. It was found that ex vivo preselection with drugs enhanced the function of the MDR1 transgene, resulting in resistance to anticancer drugs in the bone marrow of recipient animals in vivo.
Results
Chemoresistance of drug-selected hematopoietic cells transduced with MDR1-vectors The effect of drug selection on chemoresistance of the target cell population was first characterized ex vivo. Two retroviral producer cell clones, which had been generated Gene Therapy with the identical plasmid, were instrumental for these studies. An ecotropic GP+E86 MDR1/A producer clone, designated 5-20, displayed a titer of 3 × 10 6 c.f.u./ml. As a model for unsatisfactory gene transfer, a PA317-derived producer clone, designated MA1, was used. The titer of this cell line had decreased to 3 × 10 3 c.f.u./ml by the time of the current experiments.
After transduction in coculture, murine bone marrow cells were selected for 4 days in the presence of colchicine or daunomycin, two structurally unrelated substrates of P-gp. As a control, cells were analyzed that were transduced with MDR1 vectors, followed by culturing without drug. An additional control consisted of bone marrow cells transduced under identical conditions with a vector, pWE-GC, which did not confer chemoresistance. Chemoresistance was determined in multipotent, clonogenic progenitor cells (CFU-Mix).
Hematopoietic progenitor cells transduced in coculture with high-titer GP+E86 MDR1/A producer cells displayed high levels of cross-resistance to daunomycin and colchicine ( Figure 1 ). Drug selection with either 50 ng/ml colchicine or 30 ng/ml daunomycin further increased chemoresistance. In this model, colchicine was somewhat more effective in raising resistance levels than daunomycin. By elimination of cells that were poorly protected against colchicine, the entire cell progenitor population that survived short-term selection was rendered crossresistant to high drug concentrations (Figure 1 ). Hematopoietic cells transduced with a control vector that did not confer drug resistance could not be selected at these dose levels.
Next, we determined whether exposure to drugs would also improve the function of the MDR1 transgene in the target population if the gene was transferred under inefficient conditions with MA1 producer cells. Due to the low titer of these viral producers, hematopoietic cells harvested from cocultures with MA1 cells displayed no chemoresistance over the level of the negative controls ( Figure 2 ). Nevertheless, significant drug resistance was detectable if hematopoietic cells were exposed to either colchicine or daunomycin after transduction. For instance, only 7% of non-selected MDR1-transduced progenitor cells retained the ability to form colonies in the presence of 75 ng/ml colchicine. In contrast, hematopoietic cells transduced in the same coculture, but selected with colchicine contained 30% clonogenic cells resistant to this concentration of colchicine. Similarly, 26% of daunomycin-selected bone marrow cells were resistant to this concentration of colchicine. Furthermore, the frequency of daunomycin-selected colonies resistant to 45 ng/ml of colchicine was greater than 40% above the number of the respective unselected cells.
Ten per cent of colonies from daunomycin-selected bone marrow cells were clonogenic in the presence of 125 ng/ml of daunomycin while no such colonies were detected in MDR1-transduced, but unselected cells. The increased drug resistance of preselected cells was particularly noticeable at high dose levels because the low endogenous resistance of some hematopoietic cells protected them at low drug concentrations, eg colchicine at 15 ng/ml. In conclusion, drug selection can partially compensate for low transduction efficiency.
Notably, not all MDR1-transduced hematopoietic cells that had been preselected with colchicine at 50 ng/ml were subsequently resistant to 45 ng/ml of colchicine in 
8% methylcellulose supplemented with growth factors, and either colchicine (a) or daunomycin (b) at indicated concentrations. After 7 days the number of colonies consisting of more than 50 cells was counted with a stereoscopic microscope. As a negative control, cells were transduced with supernatants from pWE-GC producer cells which conferred no resistance to P-gp substrates. Results represent means and standard deviations from three experiments.
the clonogenic assay ( Figure 2 ). Thus, some cells were not sufficiently protected to withstand sustained drug treatment although they retained their clonogenicity during the brief selection period. This was not observed if hematopoietic cells were transduced with viruses from GP+E86 MDR1/A producers. The gene transfer efficiency, therefore, affected not only the frequency of resistant colonies, but also levels of resistance displayed by these colonies.
Engraftment of drug-selected hematopoietic cells in lethally irradiated mice Next, we investigated whether protection of drug-treated bone marrow cells by MDR1 gene transfer was sufficient to rescue lethally irradiated mice. Since hematopoietic cells cultured ex vivo in the presence of growth factors may loose their stem cell properties, it was first confirmed that hematopoietic cells transduced with MDR1 vectors reliably repopulated recipient bone marrow. In two independent experiments, five of five and seven of eight lethally irradiated mice were rescued with 1 × 10 6 cells and survived at least 30 days after transplantation. Similarly, six of seven mice were rescued with equal numbers of bone marrow cells transduced with the non-MDR1 control vector, pWE-GC. An overview of conditions of transduction and selection as well as the survival of the recipient mice is shown in Table 1 .
The total duration of maintenance of hematopoietic cells in tissue culture was critical in these experiments. This period consisted of prestimulation, coculture and selection. As opposed to the above-described results obtained with an ex vivo period of 6 days, longer culture periods reduced the hosts' probability of survival. Only one of nine animals survived after transplantation with 2.5 × 10 6 non-selected, MDR1-transduced cells that had been grown ex vivo for 8 days. This experiment also included seven mice that had been given 2.5 × 10 6 progenitor cells selected in colchicine (30 ng/ml) for 4 days. Only one animal from this group survived. Thus, selection has to be performed within a limited period.
Four mice were injected with 1 × 10 6 bone marrow cells that had been transduced with retrovirus from the MA1 producer cells and selected in 50 ng/ml of colchicine for 48 h; three of them were rescued. In contrast, all seven mice reconstituted with an identical number of bone marrow cells selected in daunomycin (30 ng/ml) died between 6 and 14 days after irradiation. Pathological examination of two animals revealed bone marrow aplasia. In a consecutive experiment six recipient mice were kept under sterile laminar air flow and given tetracycline orally, beginning 2 days before irradiation and continued for 3 weeks after the transplantation. Even with these precautions 1 × 10 6 daunomycin-selected bone marrow cells failed to rescue the recipients. The choice of a selective agent appears to be critical for engraftment of progenitor cells in recipient animals. Furthermore, the capacity of drug-selected cells to engraft lethally irradiated animals was largely dependent on the efficiency of protection by MDR1 gene transfer. If GP+E86 MDR1/A producers were used instead of MA1 cells, two of three mice transplanted under otherwise identical conditions were rescued with daunomycinselected cells.
P-gp expression in bone marrow of mice transplanted with drug-selected hematopoietic cells After engraftment of transduced bone marrow (30 to 45 days after transplantation), recipient mice were killed and analyzed for P-gp expression in bone marrow. Most mice that had been reconstituted with non-selected bone marrow cells expressed P-gp at low levels ( Figure 3a) . In contrast to expectations, gene transfer by coculture with GP+E86 MDR1/A retroviral producer cells did not ensure high-level P-gp expression in recipient marrow since in one animal transplanted with cells transduced with this vector P-gp was virtually undetectable (Figure 3a) . However, all mice that had engrafted with drug-selected bone marrow cells expressed human P-gp in their bone marrow. The expression levels were significantly higher than those of mice transplanted with unselected cells although variation from one animal to another was noted (summarized in Table 2a ). Two mice that had received colchicine-selected bone marrow disGene Therapy played high P-gp expression (Figure 3b) , which was observed in none of the mice reconstituted with unselected cells. As shown in Figure 3c , bone marrow from animals transplanted with a non-MDR1 vector or untreated mice did not react with monoclonal antibody MRK16, which is specific for the human MDR1 gene product.
To demonstrate active drug efflux, bone marrow cells were obtained from several recipient mice and analyzed for extrusion of rhodamine-123, a fluorescent P-gp substrate. A fraction of bone marrow cells from mice engrafted with drug-selected cells displayed reduced rhodamine-123 accumulation due to active efflux (Figure 4a ). The specificity of this efflux was confirmed by addition of a P-gp inhibitor, verapamil, which causes multidrug resistant cells to accumulate more rhodamine-123. Up to 54% of bone marrow cells from these recipient mice expressed functional P-gp (mean 32.9%). In contrast, cells from mice engrafted with unselected cells effluxed rhodamine at levels that were not significantly different from the ones seen with negative controls (Table 2a ). The assay was performed under conditions which failed to detect the low activities of endogenous drug transporters in bone marrow from untreated animals or mice that had received hematopoietic cells transduced with a non-MDR1 vector (Figure 4c ).
Drug resistance of recipient bone marrow in vivo
The bone marrow of only one of six recipient mice transplanted with cells that had not been selected after MDR1 gene transfer displayed resistance to colchicine over the average level of controls (Figure 5b ). These low chemoresistance levels correspond to the low P-gp expression in bone marrow of mice reconstituted with unselected MDR1-transduced cells. Although transduction with GP+E86 MDR1/A producers had rendered the bone marrow cells highly chemoresistant ex vivo, this resistance proved to be unstable after expansion in vivo in recipient animals. Thus, high transduction efficiency ex vivo does not necessarily ensure functional gene expression in vivo.
In contrast, most mice that had been reconstituted with drug-selected bone marrow cells retained higher levels of chemoresistance although these levels were not as high as in cultured donor cells ex vivo (Figure 5a ). Hematopoietic cells resistant to 75 ng/ml of colchicine were observed in four of five mice that had been reconstituted with drug-selected cells but in none of the animals engrafted with non-selected MDR1-transduced cells or Gene Therapy Figures 3 and 4 . The percentages are calculated by subtraction of the histograms obtained with the isotype control from anti-P-glycoprotein antibody MRK16. For rhodamine-123 extrusion, the histograms obtained in the absence of P-glycoprotein inhibitors were subtracted from the ones obtained in the presence of verapamil. 
(a) Mice engrafted with non-selected MDR1-transduced bone marrow cells. (b) Mice reconstituted with MDR1-transduced bone marrow cells that were selected for 48 h with colchicine (50 ng/ml) or daunomycin (30 ng/ml). (c) Negative controls: mouse transplanted with hematopoietic cells transduced with a non-MDR1 control vector and two normal, untreated mice of identical strain.
Negative controls 69.6% ± 2.0% 32.5% ± 17.6% 11.5-± 11.2% 3.1% ± 4.6% 0.0% ± 0.0% 0.0% ± 0.0%
Summarized are the results depicted in Figure 5 . Results show mean percentages ± standard deviations. Statistical comparison of treatment groups was performed using one-sided Mann-Whitney's rank sum test.
cells transduced with a control vector ( Figure 5 ). Differences between mice engrafted with drug-selected versus unselected, MDR1-transduced cells were significant (Table 2b) . Furthermore, three of five mice reconstituted with MDR1-transduced and drug-selected cells retained high-level resistance up to 90 ng/ml colchicine in a fraction of their bone marrow cells. Thus, enrichment of drug-resistant hematopoietic cells ex vivo improves chemoprotection of progenitor cells as assessed by a colony formation assay with fresh bone marrow harvested from recipient mice.
Discussion
We have shown that short-term exposure to cytotoxic drugs significantly increases the frequency of chemoresistant cells in the surviving target population of hematopoietic cells transduced with MDR1 vectors. Drug selection by exposure to colchicine or daunomycin is effective within the short period of 2 to 4 days. We have recently shown that increased mRNA and P-glycoprotein levels in drug-treated hematopoietic cells transduced with MDR1 vectors are associated with increased cDNA copy numbers, indicating that multidrug-resistant cells are enriched by clonal selection while untransduced cells are eliminated. 33 We show here that, as a result, the target population acquires increased drug resistance compared with cells transduced with MDR1 which are not exposed to drugs. This was observed both ex vivo in multipotent hematopoietic progenitors (CFU-Mix) and in vivo in bone marrow of recipient mice transplanted with drug-selected hematopoietic progenitor cells.
Hematopoietic progenitor cells which are selected with
Gene Therapy cytotoxic drugs after MDR1 transfer with a high-titer vector retained their ability to rescue lethally irradiated recipient animals. In contrast, the choice of the respective selecting agent proved to be critical if transduction was performed under suboptimal conditions. While hematopoietic progenitor cells selected with colchicine (50 ng/ml) rescued lethally irradiated mice, cells treated with daunomycin (30 ng/ml) failed to do so if chemoprotection resulted from a low-titer MDR1 vector. This result was not predicted from ex vivo clonogenicity assays (CFU-Mix) in which 25 ng/ml of daunomycin caused only a minor inhibition of the growth of colonies formed by cells that were not chemoprotected by MDR1. The discrepancy may reflect properties of different bone marrow subpopulations or the activity of the retroviral promoter in these populations. While this colony formation assay assesses populations of relatively immature, multipotent cells (as opposed to more differentiated and lineagerestricted CFU-GM or BFU-E), the hematopoietic compartment that originates repopulation in irradiated animals represents an even less differentiated cell type.
34,35
Furthermore, DNA intercalation by anthracyclines can limit the proliferative capacity of cell clones although cell death may not occur immediately. Since reconstitution of bone marrow after irradiatiation of an animal requires more cell divisions than the formation of colonies in a short-term assay, insufficient protection from the toxicity of daunomycin may be more noticeable in recipient mice. Bone marrow of recipient mice is typically oligoclonal, derived from one or from several hematopoietic cell clones, and clonal fluctuation may occur during the early engraftment period after bone marrow transplantation. 36, 37 Thus, few cell clones expressing high levels of (20) (21) (22) (23) (24) (25) 
m). After 2 h cells were spun down, resuspended and immediately analyzed by flow cytometry. Recipient mice were engrafted with (a) hematopoietic cells that were selected in colchicine (50 g/ml) after retroviral MDR1 gene transfer, or (b) unselected MDR1-transduced cells. (c) Recipient mice transplanted with hematopoietic cells transduced with a non-MDR1 vector (negative control).
P-gp due to drug selection may repopulate bone marrow, resulting in increased P-gp expression and chemoresistance. The observed variation between P-gp expression in bone marrow cells from individual mice may be related to different expression levels of individual clones and to variations of clonal engraftment. Notably, bone marrow from mice engrafted with unselected cells transduced with MDR1 vectors displayed only low or undetectable levels of P-gp expression and chemoresistance. These data are consistent with the low expression levels observed in clinical studies. [12] [13] [14] [15] We conclude that overexpression of the MDR1 gene does not confer an obvious short-term proliferative advantage over untransduced cells in vivo unless chemotherapy is administered. This result is in contrast to studies of Bunting et al 38 who recently reported enhanced proliferation of MDR1-transduced mouse hematopoietic cells after prolonged transduction ex vivo.
Efficient enrichment of cells expressing P-gp within short periods is essential because, unlike permanent cell lines, primary hematopoietic cells cannot be maintained ex vivo for extended periods without losing stem cell properties. These cells tend to differentiate in tissue cultures supplemented with growth factors, thereby reducing their capacity to repopulate bone marrow and radioprotect recipient mice. 39, 40 Growth factors are required to stimulate cell division in culture, which is a prerequisite for integration of retroviral sequences into the genome. In the present study, we found a total culture period of 6 days suitable while prolongation to 8 days resulted in engraftment failure. The length of this culture period may depend on the respective supplementation of medium with growth factors. The factor combination we employed had been useful for ex vivo expansion of human hematopoietic stem cells, and gene transfer to murine hematopoietic stem cells in previous studies. 22, 41 Culturing of hematopoietic cells for extended periods may bear safety risks in addition to loss of their capacity to rescue lethally irradiated hosts. Murine hematopoietic cells grown in the presence of growth factors for 12 days after MDR1 gene transfer led to a myeloproliferative syndrome when transplanted in non-myeloablated mice. 
Gene Therapy
In the present study, drug selection facilitated enrichment of resistant subpopulations in tissue culture even if the entire target cell population was poorly transduced, and unselected cells displayed no discernible resistance over the level of the control. The effect of selection with colchicine or daunomycin was even more marked in this target population than in efficiently transduced cells, which were highly chemoresistant without selection. Thus, both compounds are suitable for selection at the level of clonogenic progenitors. Not all cytotoxic substrates of P-gp exert their major activity towards the appropriate bone marrow subfraction. It was reported that taxol, vinblastine and navelbine were mainly active against more mature, non-clonogenic precursor cells. 32 Compounds that eliminate exclusively non-clonogenic cells may not be useful for selection because they cannot provide a selective advantage to multidrug resistant cells in the regrowing population. The dose levels for selection, colchicine at 50 ng/ml and daunomycin at 30 ng/ml, were comparable in their ability to increase the number of drug-resistant colony-forming cells in the resulting populations. However, colchicine appeared to be more practical because it is less toxic with respect to survival of recipient animals. Colchicine has been used ex vivo for selection of murine hematopoietic progenitor cells transduced with MDR1 vectors. 43 In an investigation on selection of human CD34
+ cells in tissue culture, colchicine and taxol were equally suitable for enrichment of cells transduced with wild-type MDR1. 44 Taxol-treated hematopoietic cells retain the capacity of sustained engraftment and of repopulating secondary recipient animals after re-transplantation. 21 In the current study, colchicine may be a preferred substrate for selection because the cDNA in the vector we used contained a point mutation that confers improved resistance to this agent. 45, 46 Several MDR1 mutations have been characterized that increase resistance to other compounds. 26 Since point mutations of the MDR1 cDNA affect the substrate specificity of the multidrug transporter, it appears possible to design vectors which are particularly effective for protection of hematopoietic cells against certain drugs.
Hematopoietic cells expressing P-gp can also be enriched ex vivo by immunoseparation with antibodies to P-gp. Transplantation of immunoseparated hematopoietic cells enriched for P-gp expression led to improved long-term expression of P-gp in recipient bone marrow. 47 However, this technique cannot be used for selection of multidrug resistant cells in vivo. In addition to MDR1, transfer of other drug resistance genes has been used for chemoprotection of hematopoietic cells against certain anticancer drugs, eg O 6 -methylguanine DNA methyltransferase, which confers resistance to alkylating agents. 48 
Materials and methods
Generation and titration of retroviral producer cells Construction of plasmid pHaMDR1/A which consists of a full-length human MDR1 cDNA flanked by longterminal repeats from Harvey sarcoma virus has been reported. 52 This MDR1 cDNA contains a point mutation (G185V) which confers preferential resistance to colchicine. 45, 46 By transfection of pHaMDR1/A into PA317 packaging cells, a virus producing cell clone, designated MA1, was generated. An ecotropic retrovirus producer line GP+E86 MDR1/A, developed with the same plasmid, was kindly provided by Dr A Bank (Columbia University, New York, NY). GP+E86 MDR1/A cells were repeatedly subcloned to maintain high retroviral titers. Both cell lines were continuously selected in colchicine at 60 ng/ml. pWE-GC virus producing cells, kindly provided by Dr E Ginns (National Institute of Mental Health, NIH, Bethesda, MD), were used as a negative control. They contained a neomycin-phosphotransferase and a glucocerebrosidase cDNA, but conferred no resistance to P-gp substrates.
For assessment of retroviral titers 1 × 10 5 logarithmically growing NIH 3T3 cells were plated in 100 mm culture dishes. After 24 h the medium was replaced with filtered supernatant (0.45 m) from confluent virus producer cells in serial dilutions. Polybrene was added at 8 g/ml. Forty-eight hours later, the supernatant was removed and selection was initiated with colchicine at 60 ng/ml. The selecting medium was exchanged every 2-3 days. After 8-12 days, dishes were stained with 0.5% methylene blue dissolved in 50% (v/v) ethanol in water, and blue colonies were counted.
Preparation and transduction of hematopoietic cells
Six-to 12-week old C57BL/6 mice were obtained from NCI Frederick Cancer Research and Development Center (Frederick, MD, USA). The animals were injected i.v. with 150 mg/kg 5-fluorouracil (Sigma, St Louis, MO, USA) in PBS without calcium and magnesium. After 2-4 days bone marrow was harvested from both femurs and tibias. Large aggregates were removed by passing through a Falcon 40 m cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Single cell suspensions were prepared by repeated flushing through a sterile 20-gauge needle. Cells were washed in complete medium consisting of Iscove's modified Dulbecco's medium (IMDM, from Gibco/BRL, Gaithersburg, MD, USA), 20% fetal bovine serum (FBS, from HyClone, Logan, UT, USA), 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco/BRL).
Hematopoietic cells were prestimulated for 18 h in complete medium supplemented with 0.5 mm 2-mercaptoethanol, 20 ng/ml murine stem cell factor (SCF, from Sigma), 20 ng/ml murine interleukin (IL)-1␤ (Intergen, Purchase, NY, USA), 200 U/ml murine IL-3 (Peprotech, Rocky Hill, NJ, USA) and 200 U/ml human IL-6 (Becton Dickinson Labware). All suspension cultures of hematopoietic cells were performed in this medium at 37°C in an atmosphere containing 5% CO 2 .
Retrovirus producing cells, pregrown to confluence, were irradiated (25-30 Gy) using a 137 Cs source. Prestimulated bone marrow cells were transferred on to the bottom layer of viral producer cells and cocultured in the presence of 4 g/ml polybrene. After 48 h non-adherent cells were harvested and resuspended in fresh medium with growth factors. Twenty-four hours later either daunomycin or colchicine, respectively, were added, or cells were grown in the absence of drugs.
Reconstitution of recipient mice
Recipient mice were of the same strain and age as bone marrow donors. During the transplantation period they obtained autoclaved food and water ad libitum. In some experiments animals were transferred to sterile microisolator cages and kept under a sterile laminar air flow for 2 weeks, beginning 2 days before irradiation. In these experiments, drinking water was supplemented with tetracycline at 1 mg/ml (Sigma).
Mice were irradiated (9 Gy) using a 137 Cs source, followed by i.v. injection of 1 × 10 6 transduced and drugtreated donor cells in 200-300 l of phosphate-buffered saline (PBS) without calcium or magnesium. Viability of the donor cells was determined using Trypan blue exclusion. Each experiment included several control animals that were not transplanted with donor cells; none of them survived in any experiment. Mice were killed 30-45 days after transplantation, and bone marrow cells were analyzed for P-gp expression or chemoresistance.
Flow cytometry
Detection of human P-gp with monoclonal antibody MRK-16 by flow cytometry has been described. 22 For analysis of drug efflux mediated by P-gp, hematopoietic cells were first incubated for 20 min at 37°C in complete medium without phenol red containing rhodamine-123 (0.25 m). Cells were then spun down at 300 g. They were resuspended in medium without rhodamine-123 in the presence or in the absence of verapamil (20-25 m) . After incubation at 37°C for 2 h, cells were spun down and transferred to ice. The supernatant was removed, and fluorescence intensities were immediately assessed by flow cytometry using a FACSort cytometer (Becton Dickinson). The numbers of cells with reduced rhoda-
